IL10 and colitis: Based on these observations, testing MCC950 in animals with colitis (i.e., DSS, TNBS, or IL-10−/−) would allow a better characterization of the anti-inflammatory effects resulting from selective inhibition of canonical and non-canonical NLRP3 inflammasome activation.